C Michael Gibson: Mike Sharma and I Discuss The Results of The Phase III OCEANIC-STROKE Trial
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Dr. Mike Sharma and I discuss the results of the phase III OCEANIC-STROKE Trial: In secondary stroke prevention the Factor Xi inhibitor Asundexian reduced the risk of recurrent ischemic stroke at 1 year by 26%.
The absolute reduction was such that only 53 people would we need to be treated to prevent another stroke at 1 year.
There was no increase in mild or severe bleeding or intracranial bleeding
63% of people were on DAPT at study start, and they had the same benefit as people on antiplatelet monotherapy
Similar benefit in medium to large vessel ischemic stroke, lacunar stroke and stroke of unidentified origin
All benefit with no increase in bleeding risk
View slides here.”
Stay updated with Hemostasis Today.
-
Feb 5, 2026, 12:45Davide Bartoli Honors CVSN AHA and ISC26 Stroke Nursing Symposium Leadership
-
Feb 5, 2026, 12:26Rosa Hart: Pre-con Day at ISC26 Was Rousing!
-
Feb 5, 2026, 09:05Daniel Torrent: From Early Hemodynamic Recovery to Improved Survival in Pulmonary Embolism
-
Feb 5, 2026, 09:00Khelvin Jocson: Using LPA to Guide Aspirin Decisions in Primary Prevention
-
Feb 5, 2026, 08:56Rick Kapur: PhD Position on Investigating the Role of Platelet Extracellular Vesicles in Amsterdam
-
Feb 5, 2026, 08:49Mahesan Subramaniam: The Role of Maternal Genetics in the Inheritance of Intelligence
-
Feb 5, 2026, 08:29Filippo Cademartiri: What Happened When Guidelines Shifted Against Aspirin for Primary Cardiovascular Prevention
-
Feb 5, 2026, 07:12ISC26 Paul Dudley White International Scholar Award Presented to Umberto Pensato and Team
-
Feb 5, 2026, 05:14Parandzem Khachatryan: Do You Agree That a Doctor’s Greatest Strength is Not Their Skill, But Their Curiosity?